JP2010530369A5 - - Google Patents

Download PDF

Info

Publication number
JP2010530369A5
JP2010530369A5 JP2010511658A JP2010511658A JP2010530369A5 JP 2010530369 A5 JP2010530369 A5 JP 2010530369A5 JP 2010511658 A JP2010511658 A JP 2010511658A JP 2010511658 A JP2010511658 A JP 2010511658A JP 2010530369 A5 JP2010530369 A5 JP 2010530369A5
Authority
JP
Japan
Prior art keywords
acid
interferon
cell
irna agents
skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010511658A
Other languages
English (en)
Japanese (ja)
Other versions
JP5485146B2 (ja
JP2010530369A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2008/057476 external-priority patent/WO2008152131A2/en
Publication of JP2010530369A publication Critical patent/JP2010530369A/ja
Publication of JP2010530369A5 publication Critical patent/JP2010530369A5/ja
Application granted granted Critical
Publication of JP5485146B2 publication Critical patent/JP5485146B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010511658A 2007-06-15 2008-06-13 α−ＥＮａＣ発現のＲＮＡｉ阻害 Expired - Fee Related JP5485146B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP07110376 2007-06-15
EP07110376.6 2007-06-15
EP07114265 2007-08-13
EP07114265.7 2007-08-13
PCT/EP2008/057476 WO2008152131A2 (en) 2007-06-15 2008-06-13 Rnai inhibition of alpha-enac expression

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014029519A Division JP5719047B2 (ja) 2007-06-15 2014-02-19 α−ＥＮａＣ発現のＲＮＡｉ阻害

Publications (3)

Publication Number Publication Date
JP2010530369A JP2010530369A (ja) 2010-09-09
JP2010530369A5 true JP2010530369A5 (enExample) 2011-07-28
JP5485146B2 JP5485146B2 (ja) 2014-05-07

Family

ID=40130244

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2010511658A Expired - Fee Related JP5485146B2 (ja) 2007-06-15 2008-06-13 α−ＥＮａＣ発現のＲＮＡｉ阻害
JP2014029519A Expired - Fee Related JP5719047B2 (ja) 2007-06-15 2014-02-19 α−ＥＮａＣ発現のＲＮＡｉ阻害
JP2015055783A Expired - Fee Related JP6193906B2 (ja) 2007-06-15 2015-03-19 α−ＥＮａＣ発現のＲＮＡｉ阻害
JP2017149211A Expired - Fee Related JP6680728B2 (ja) 2007-06-15 2017-08-01 α−ＥＮａＣ発現のＲＮＡｉ阻害
JP2020046007A Active JP7157775B2 (ja) 2007-06-15 2020-03-17 α－ＥＮａＣ発現のＲＮＡｉ阻害
JP2022162309A Pending JP2022188234A (ja) 2007-06-15 2022-10-07 α－ＥＮａＣ発現のＲＮＡｉ阻害

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2014029519A Expired - Fee Related JP5719047B2 (ja) 2007-06-15 2014-02-19 α−ＥＮａＣ発現のＲＮＡｉ阻害
JP2015055783A Expired - Fee Related JP6193906B2 (ja) 2007-06-15 2015-03-19 α−ＥＮａＣ発現のＲＮＡｉ阻害
JP2017149211A Expired - Fee Related JP6680728B2 (ja) 2007-06-15 2017-08-01 α−ＥＮａＣ発現のＲＮＡｉ阻害
JP2020046007A Active JP7157775B2 (ja) 2007-06-15 2020-03-17 α－ＥＮａＣ発現のＲＮＡｉ阻害
JP2022162309A Pending JP2022188234A (ja) 2007-06-15 2022-10-07 α－ＥＮａＣ発現のＲＮＡｉ阻害

Country Status (26)

Country Link
US (12) US7718632B2 (enExample)
EP (7) EP2224005B1 (enExample)
JP (6) JP5485146B2 (enExample)
KR (2) KR101821081B1 (enExample)
CN (1) CN101778941B (enExample)
AR (1) AR066984A1 (enExample)
AU (1) AU2008263876B2 (enExample)
BR (1) BRPI0813680A8 (enExample)
CA (1) CA2690674C (enExample)
CL (1) CL2008001756A1 (enExample)
CO (1) CO6251331A2 (enExample)
CR (1) CR11136A (enExample)
CU (1) CU23774A3 (enExample)
EA (1) EA200901653A1 (enExample)
EC (1) ECSP099794A (enExample)
ES (6) ES2432644T3 (enExample)
GT (1) GT200900315A (enExample)
IL (1) IL202366A0 (enExample)
MA (1) MA31564B1 (enExample)
MX (1) MX2009013609A (enExample)
PE (1) PE20090942A1 (enExample)
SG (3) SG169988A1 (enExample)
SV (1) SV2009003434A (enExample)
TN (1) TN2009000521A1 (enExample)
TW (3) TWI552753B (enExample)
WO (1) WO2008152131A2 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2322145T3 (es) * 2002-07-26 2009-06-17 Novartis Vaccines And Diagnostics, Inc. Moleculas pequeñas modificadas de adn inerferente y procedimiento de uso.
KR100473148B1 (ko) * 2002-11-27 2005-03-10 (주)텔리언 버스트모드 패킷 전달을 위한 정합장치 및 방법
US8765704B1 (en) 2008-02-28 2014-07-01 Novartis Ag Modified small interfering RNA molecules and methods of use
JP2008514242A (ja) * 2004-10-01 2008-05-08 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 改変型の小さい干渉ｒｎａ分子および使用方法
AR066984A1 (es) 2007-06-15 2009-09-23 Novartis Ag Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia)
KR20110095391A (ko) * 2008-11-26 2011-08-24 머크 샤프 앤드 돔 코포레이션 짧은 간섭 핵산 (ｓｉＮＡ)을 사용한 상피 나트륨 채널 (ＥＮａＣ) 유전자 발현의 ＲＮＡ 간섭 매개 억제
EP2756845B1 (en) * 2009-04-03 2017-03-15 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibition of KRAS by asymmetric double-stranded RNA
CN103275978B (zh) * 2009-04-03 2014-10-29 百奥迈科生物技术有限公司 修饰的小干扰核酸及其制备方法
WO2010111891A1 (zh) * 2009-04-03 2010-10-07 北京大学 修饰的寡聚核酸分子及其制备方法和应用
US20120207818A1 (en) * 2009-07-14 2012-08-16 Shinohara Fumikazu Composition for suppressing expression of target gene
DK3252068T3 (da) * 2009-10-12 2025-08-25 Larry J Smith Metoder og sammensætninger til modulering af genekspression ved anvendelse af oligonukleotidbaserede lægemidler administreret in vivo eller in vitro
MX339050B (es) 2009-12-18 2016-05-09 Novartis Ag Composiciones organicas para tratar las enfermedades relacionadas con hsf1.
EP3061824B1 (en) * 2010-04-23 2018-08-29 Arrowhead Pharmaceuticals, Inc. Organic compositions to treat beta-enac-related diseases
CN103703141B (zh) * 2011-04-08 2016-08-17 伯乐实验室公司 具有降低的非特异性活性的pcr反应混合物
EP2699271A4 (en) 2011-04-20 2015-10-07 Larry J Smith METHODS AND COMPOSITIONS FOR MODULATING GENE EXPRESSION USING COMPONENTS THAT SELF-ASSEMBLED IN CELLS AND PRODUCE RNAI ACTIVITY
EP3693464A3 (en) * 2011-06-21 2020-12-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibition of expression of apolipoprotein c-iii (apoc3) genes
WO2013030778A2 (en) 2011-09-02 2013-03-07 Novartis Ag Organic compositions to treat hsf1-related diseases
JP7291624B2 (ja) 2016-11-01 2023-06-15 アローヘッド ファーマシューティカルズ インコーポレイテッド アルファ－ｖベータ－６インテグリンリガンド及びその使用
KR20200024793A (ko) * 2017-07-06 2020-03-09 애로우헤드 파마슈티컬스 인코포레이티드 알파-ENaC의 발현을 억제하기 위한 RNAi 작용제 및 사용 방법
CA3074739A1 (en) * 2017-10-31 2019-05-09 Ionis Pharmaceuticals, Inc. Modulators of enac expression
BR112020006901A2 (pt) * 2017-11-01 2020-10-13 Arrowhead Pharmaceuticals, Inc. ligantes de integrina e usos dos mesmos
CN109364248B (zh) * 2018-10-16 2021-05-18 哈尔滨医科大学 ENaC及其抑制剂在预防、缓解和/或治疗动脉粥样硬化中的应用
EP4021413A4 (en) * 2019-08-30 2023-07-05 United States Government as Represented by The Department of Veterans Affairs LIPOSOMAL TROPONOID COMBINATION FORMULATIONS
US12415840B2 (en) 2020-02-21 2025-09-16 Brookhaven Science Associates, Llc Modified form of oleosin that when expressed in plants leads to increased triacylglycerol (oil) accumulation
EP4319765A1 (en) 2021-04-08 2024-02-14 Arrowhead Pharmaceuticals, Inc. Rnai agents for inhibiting expression of receptor for advanced glycation end-products, compositions thereof, and methods of use
US11957178B2 (en) 2021-11-15 2024-04-16 Apackaging Group Llc Aerosol actuator

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4426330A (en) * 1981-07-20 1984-01-17 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4534899A (en) * 1981-07-20 1985-08-13 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4837026A (en) * 1985-10-03 1989-06-06 Rajakhyaksha Vithal J Transdermal and systemic preparation and method
DE3604625C2 (de) * 1986-02-14 1994-01-20 Bmw Rolls Royce Gmbh Gasturbine
US4920016A (en) 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
US4837028A (en) * 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5451670A (en) * 1987-12-09 1995-09-19 City Of Hope Restriction fragment length polymorphism test for haplotyping domesticated fowl
GB8824593D0 (en) 1988-10-20 1988-11-23 Royal Free Hosp School Med Liposomes
US5013566A (en) * 1988-12-19 1991-05-07 Sampson Michael James Process for obtaining improved yields from plants used for hay making by using a coating agent
US5328470A (en) * 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5356633A (en) * 1989-10-20 1994-10-18 Liposome Technology, Inc. Method of treatment of inflamed tissues
US5225212A (en) * 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5665710A (en) * 1990-04-30 1997-09-09 Georgetown University Method of making liposomal oligodeoxynucleotide compositions
JP3220180B2 (ja) * 1991-05-23 2001-10-22 三菱化学株式会社 薬剤含有タンパク質結合リポソーム
JP3351476B2 (ja) * 1993-01-22 2002-11-25 三菱化学株式会社 リン脂質誘導体及びそれを含有するリポソーム
RU2123492C1 (ru) * 1993-02-19 1998-12-20 Ниппон Синяку Ко., Лтд Производные глицерина, средство для доставки физиологически активного вещества и фармацевтическая композиция
US5395619A (en) 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
CA2137297C (en) * 1993-12-06 2000-04-18 Tsuyoshi Miyazaki Reactive vesicle and functional substance-fixed vesicle
JP3543347B2 (ja) * 1994-01-24 2004-07-14 日本油脂株式会社 点火薬造粒物の製造方法
US5543152A (en) * 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5820873A (en) 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
US5756122A (en) 1995-06-07 1998-05-26 Georgetown University Liposomally encapsulated nucleic acids having high entrapment efficiencies, method of manufacturer and use thereof for transfection of targeted cells
DE69629702T2 (de) 1995-08-01 2004-06-17 Isis Pharmaceuticals, Inc., Carlsbad Liposomale oligonukleotidzusammensetzungen
US5858397A (en) 1995-10-11 1999-01-12 University Of British Columbia Liposomal formulations of mitoxantrone
US5998203A (en) 1996-04-16 1999-12-07 Ribozyme Pharmaceuticals, Inc. Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
US5994316A (en) 1996-02-21 1999-11-30 The Immune Response Corporation Method of preparing polynucleotide-carrier complexes for delivery to cells
US6218108B1 (en) * 1997-05-16 2001-04-17 Research Corporation Technologies, Inc. Nucleoside analogs with polycyclic aromatic groups attached, methods of synthesis and uses therefor
US5865710A (en) * 1996-08-01 1999-02-02 Wilson-Hyde; Cynthia Step aerobic platform
WO1998040516A1 (en) 1997-03-11 1998-09-17 Yale University Method to diagnose and treat pathological conditions resulting from deficient ion transport such as pseudohypoaldosteronism type-1
DE69834038D1 (de) * 1997-07-01 2006-05-18 Isis Pharmaceutical Inc Zusammensetzungen und verfahren zur verabreichung von oligonukleotiden über die speiseröhre
US5976849A (en) * 1998-02-05 1999-11-02 Zeneca Limited Human E3 ubiquitin protein ligase
WO2000053722A2 (en) 1999-03-10 2000-09-14 Phogen Limited Delivery of nucleic acids and proteins to cells
EP1873259B1 (en) * 2000-12-01 2012-01-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. RNA interference mediated by 21 and 22nt RNAs
EP1399593A2 (en) 2001-05-16 2004-03-24 Novartis AG Genes expressed in breast cancer as prognostic and therapeutic targets
EP1478655A4 (en) 2001-12-31 2006-05-10 Algos Therapeutics Inc METHODS AND SUBSTANCES FOR ENAC-BETA MODULATION
ES2322145T3 (es) 2002-07-26 2009-06-17 Novartis Vaccines And Diagnostics, Inc. Moleculas pequeñas modificadas de adn inerferente y procedimiento de uso.
JP2004121218A (ja) 2002-08-06 2004-04-22 Jenokkusu Soyaku Kenkyusho:Kk 気管支喘息または慢性閉塞性肺疾患の検査方法
GB0218970D0 (en) 2002-08-14 2002-09-25 Creative Peptides Sweden Ab Fragments of Insulin c-peptide
EP2314691A3 (en) * 2002-11-14 2012-01-18 Dharmacon, Inc. Fuctional and hyperfunctional siRNA
AU2003293124A1 (en) 2002-11-27 2004-06-23 Artesian Therapeutics, Inc. Heart failure gene determination and therapeutic screening
AU2002368410A1 (en) 2002-11-29 2004-06-23 Basf Aktiengesellschaft Methods for the production of methionine
DE10305213A1 (de) * 2003-02-07 2004-08-26 Florian Prof. Dr.med. Lang Verwendung eines neuen Polymorphismus im hsgk1-Gen zur Diagnose der Hypertonie und Verwendung der sgk-Genfamilie zur Diagnose und Therapie des Long-Q/T-Syndroms
US20050095225A1 (en) * 2003-03-31 2005-05-05 Engelhardt John F. Compounds and methods for pharmico-gene therapy of epithelial sodium channel associated disorders
US7723509B2 (en) * 2003-04-17 2010-05-25 Alnylam Pharmaceuticals IRNA agents with biocleavable tethers
AU2003224132A1 (en) 2003-04-24 2004-11-19 Galapagos Genomics N.V. Effective sirna knock-down constructs
US20050256071A1 (en) * 2003-07-15 2005-11-17 California Institute Of Technology Inhibitor nucleic acids
JP4530335B2 (ja) * 2004-02-03 2010-08-25 独立行政法人科学技術振興機構 膀胱に発現する上皮型ナトリウムチャネルに対する阻害薬
CN101052717A (zh) * 2004-05-11 2007-10-10 α基因株式会社 诱发rna干扰的多核苷酸以及使用该多核苷酸的基因表达抑制方法
SE0402832D0 (sv) * 2004-11-18 2004-11-18 Astrazeneca Ab Methods
US20060166234A1 (en) * 2004-11-22 2006-07-27 Barbara Robertson Apparatus and system having dry control gene silencing compositions
US7361752B2 (en) * 2004-12-14 2008-04-22 Alnylam Pharmaceuticals, Inc. RNAi modulation of MLL-AF4 and uses thereof
EP1948674A4 (en) * 2005-11-02 2009-02-04 Protiva Biotherapeutics Inc MODIFIED SIRNA MOLECULES AND APPLICATIONS THEREOF
WO2007070509A2 (en) * 2005-12-13 2007-06-21 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Epithelial sodium channel inhibiting agents and uses therefor
KR101133799B1 (ko) 2006-08-18 2012-04-24 에프. 호프만-라 로슈 아게 폴리뉴클레오타이드의 생체내 전달을 위한 다가접합체
AU2007306542B2 (en) 2006-10-11 2013-08-01 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Influenza targets
AR066984A1 (es) * 2007-06-15 2009-09-23 Novartis Ag Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia)

Similar Documents

Publication Publication Date Title
JP2010530369A5 (enExample)
JP6901421B2 (ja) 半フッ化アルカンを基礎にした局所薬学的組成物
JP2554419B2 (ja) エステル及びアミドを含んで成るそう痒用製剤
ES2673219T3 (es) Composición para la entrega transdérmica de agentes activos
AU2005294805B2 (en) A mixture for transdermal delivery of low and high molecular weight compounds
Zhang et al. Co-delivery of evodiamine and rutaecarpine in a microemulsion-based hyaluronic acid hydrogel for enhanced analgesic effects on mouse pain models
JP7082041B2 (ja) 薬剤送達装置および生物活性薬剤
US20110091420A1 (en) Injectable Sustained-Release Pharmaceutical Formulation and the Preparation Method Thereof
Roy et al. Review article on permeation enhancers: a major breakthrough in drug delivery technology
CA2556993A1 (en) Pimecrolimus foam composition containing hexylene glycol, optionally oleyl alcohol, dimethylisosorbide and/or medium chain triglycerides
FI76255C (fi) Foerfarande foer framstaellning av en antiviral foerbaettrad topisk olja-i-vatten-komposition av 9-(2-hydroxietoximetyl)guanin eller ett farmaceutiskt godtagbart salt eller ester daerav.
RS59012B1 (sr) Testosteronske formulacije
CN111491625B (zh) 溶解尿酸单钠以治疗痛风
EP1558227B1 (en) Injectable 2,6-diisopropylphenol-containing anesthetic composition and methods
Prasad et al. Transdermal delivery of methotrexate: past, present and future prospects
CA2725972A1 (en) Paeoniflorin preparations and uses thereof for fat reduction
Salehi et al. Absorption enhancer approach for protein delivery by various routes of administration: a rapid review
Nabila et al. Transdermal Insulin Delivery Using Ionic Liquid-Mediated Nanovesicles for Diabetes Treatment
Kokura et al. Efficacy of hyperthermia and polyunsaturated fatty acids on experimental carcinoma
EP1765310B1 (en) A mixture for transdermal delivery of low and high molecular weight compounds
WO2007146126A3 (en) Insulin composition
CN1583175A (zh) 具有皮肤靶向性的药物组合物及其制备方法和用途
GHANEM A review on recent advances in transdermal drug delivery systems of tamsulosin
WO2008041116A2 (en) Formulations of active principles incorporated in slns suitable for transdermal administration
US20130210867A1 (en) Methods and compositions for enhancing female sexual arousal and treating female sexual dysfunction